Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
April 19th 2024According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.
Read More
Oculogenex founder talks about collaboration with NASA and ISS on experiment in macular degeneration
April 11th 2024Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.
Read More
Orbis, FundamentalVR unveil VR solution that may democratize ophthalmic surgical training
April 6th 2024According to the companies, the tool is affordable, portable, scalable, and intentionally designed to train surgeons in low- and middle-income countries, home to 9 out of 10 people with vision loss due to the difficulty of accessing eye care. The VR tool is being unveiled at the American Society of Cataract and Refractive Surgery Annual Meeting in Boston.
Read More
ASCRS 2024: Refractive cataract surgery in DED afflicted eyes
April 5th 2024Jennifer Loh, MD, sat down to discuss her presentation on major eye issues that can interfere with refractive cataract surgery, specifically dry eye disease, at this year's ASCRS meeting held in Boston, Massachusetts.
Read More